Ocugen announces OCU400 provisional approval in Bahamas, OCU410 Phase 3 dosing starts

Ocugen announces OCU400 provisional approval in Bahamas, OCU410 Phase 3 dosing starts
Ocugen gains Bahamas OCU400 nod

Ocugen reported key milestones for its ophthalmology pipeline, including provisional approval and priority designation in the Bahamas for OCU400, as well as a new licensing agreement in the MENA region.

The company also initiated Phase 3 dosing for OCU410 and shared topline results from OCU400 Phase 3 are anticipated in the first quarter of 2027. Ocugen ended the quarter with $84.6 million in cash.

Earlier, Ocugen launched a modifier gene therapy using master regulator genes to address major blindness diseases through network influence, as detailed in a previous announcement. The company also signed an OCU400 licensing agreement with Roots Pharmaceutical for the MENA region with up to $259 million in potential milestones and royalties, according to terms released last year. These steps have supported Ocugen's ongoing expansion of its ophthalmology pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.